Corebridge Financial and Equitable Holdings have agreed to an all-stock merger valued at approximately $22 billion that will create a life insurance, annuity, wealth and asset management company ...

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a ...

Although one GLP-1 study made national headlines about the drug class’ potential use in addiction treatment, other research indicates GLP-1s could increase the risk of bone injuries and are less ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. New research suggests prolonged GLP-1 use may be linked ...

A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn’t use a patch. He ...

Please provide your email address to receive an email when new articles are posted on . Cutaneous adverse events with GLP-1 receptor agonists are rare but can include rash and pruritus. Clinicians ...

As GLP-1s continue to surge in demand, older patients in your practice may inquire about these medications for their weight-loss efforts. Although they are known to improve conditions such as high ...

A sizable percentage of people using Novo (NVO) and Lilly’s (LLY) GLP-1 drugs may be able to sustain their weight loss effects even months after discontinuing the popular obesity drugs, Reuters ...

The incidence of colorectal cancer among users of GLP-1RAs was approximately 36% lower than that observed among aspirin users. The use of GLP-1 receptor antagonist (GLP-1RA) therapy has led to a ...

Sustained GLP-1 use slows medical cost growth, according to findings published Jan. 13 from professional services firm Aon. The firm analyzed 192,000 GLP-1 users from July 2022 to March 2025, ...